Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan. Clin Exp Nephrol. 2008;12:277–91.PubMedCrossRef 2. Bajema IM, Hagen EC, Hansen BE, et al. The renal histopathology in systemic vasculitis: an international Geneticin survey study click here of inter- and intra-observer agreement. Nephrol Dial Transplant. 1996;11:1989–95.PubMedCrossRef 3. Lind
De, van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17:2264–74.CrossRef 4. Yamagata K, Usui J, Saito C, et al. ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes. Clin Exp Nephrol. 2012;16:580–8.PubMedCrossRef 5. Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628–36.PubMedCrossRef 6. Fujimoto S, Uezono S, Hisanaga S, et al. Incidence of ANCA-associated primary renal vasculitis in the Miyazaki Prefecture: the Akt inhibitor first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol.
2006;1(5):1016–22.PubMedCrossRef 7. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus committee. Arthritis Rheum. 1994;37:187–92.PubMedCrossRef 8. Chang DY, Wu LH, Liu G, et al. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant. 2012;27:2343–9.PubMedCrossRef 9. Watts RA, Scott DG, Jayne DR, et al. Renal vasculitis in Japan and the UK—are there differences in epidemiology
and clinical phenotype? Nephrol Dial Transplant. Phosphatidylinositol diacylglycerol-lyase 2008;23:3928–31.PubMedCrossRef 10. Watts RA, Lane SE, Scott DG, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis. 2001;60:1156–7.PubMedCrossRef”
“Introduction Chronic kidney disease (CKD) is the leading risk factor for cardiovascular disease (CVD), a great threat to health and an economic burden [1]. In Japan, the prevalence of end-stage kidney disease (ESKD) requiring renal replacement therapy has been increasing over the last three decades. There were 38,893 new cases in 2010, bringing the total number of cases in Japan to 304,592 [2]. Since the number of patients requiring dialysis has continued to increase [3], there appear to be an enormous number of latent cases of CKD in the Japanese population. In a recent study, Imai et al. reported the prevalence of CKD by calculating the estimated glomerular filtration rate (eGFR) using an equation that estimates GFR based on data from the Japanese annual health check program in 2005 [4]. They predicted that 13 % of the Japanese adult population (approximately 13.3 million people) would have CKD in 2005.